Navigation Links
Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)
Date:5/23/2013

ATLANTA, May 23, 2013 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease treatments, announced today that it will present new results on its antiviral program to 'prevent' PML at an industry conference sponsored by the PML Consortium (composed of Pfizer, Bristol-Meyers Squibb, Roche and Biogen Idec).  JC polyomavirus (JCV) is the causative agent of Progressive Multifocal Leukoencephalopathy (PML). IkT-001Pro, a host-directed tyrosine kinase inhibitor in an extended release formulation, can clear JC polyomavirus (JCV) infection in at least some patients and is active against the form of the virus that infects the majority of human beings. The Company will present preliminary outcomes of its proposed treatment to 'prevent' PML.  This oral medication, taken once or twice daily, is compatible with many different monoclonal antibody-based therapies and may offer a general solution to JCV infection as a companion therapeutic.

"JCV infection progresses to PML only in patients with chronic or drug-induced immune suppression. The ability to clear JCV infection in at least some patients is encouraging.  Further clinical evaluation confirming preliminary results is underway in several patient groups," said Milton H. Werner Ph.D., Chief Executive Officer and President of Inhibikase Therapeutics. 

About Inhibikase Therapeutics

Founded in 2008, Inhibikase Therapeutics is a private biopharmaceutical company developing novel, small-molecule compounds to treat bacterial, viral, fungal and parasitic diseases through a common mechanism of action, often involving a single drug.  Its pipeline of validated targets treat diseases therapeutically and prophylactically.  By inhibiting human pathways used by multiple bacteria and viruses for reproduction in the patient, the Company's compounds resolve infection with a lower likelihood of stimulating resistance. Inhibikase Therapeutics is also developing a broad-spectrum antiviral specific for enveloped viruses, opening new avenues for vaccine development and biodefense. For more information, please visit the Company's website at www.inhibikase.com.

For Further Information Contact:

Milton H. Werner , PhD
President & CEO
Inhibikase Therapeutics, Inc.
(917) 494-0831 (m)
mhwerner@inhibikase.com


'/>"/>
SOURCE Inhibikase Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
2. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
3. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
4. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
5. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
6. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
7. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
9. Novelos Therapeutics Provides Product Pipeline Update
10. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
11. Mast Therapeutics Reports First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/3/2020)... , ... January 03, 2020 , ... In Partnership with ... dental services for low-income, underinsured individuals at its Burleson, TX office on February 8th. ... fillings , cleanings and extractions . For more information, please ...
(Date:1/3/2020)... ... January 03, 2020 , ... Complia Health announced today the ... will offer enterprise solutions for home, residential and community care in Canada, Australia ... and will move forward under the AlayaCare brand. , Procura has delivered home, ...
(Date:1/2/2020)... ... January 02, 2020 , ... ... presentations that address all levels of psychiatric-mental health nursing administration, education, practice, ... presentations to 1800+ registered and advanced practice nurses. Nurses from varied backgrounds ...
Breaking Medicine Technology:
(Date:1/10/2020)... ... January 10, 2020 , ... WellHaven Pet Health, a family of companion animal ... community coming in February 2020, LEAD WELL with WOMEN. The community will be showcased ... vision of LEAD WELL with WOMEN is to empower women, engage all, connect, and ...
(Date:1/10/2020)... OAK BROOK, Ill. (PRWEB) , ... January 10, ... ... Nursing (BCEN) today announced that its Certified Pediatric Emergency Nurse (CPEN) ... Specialty Nursing Certification (ABSNC). , The CPEN is a national board certification ...
(Date:1/8/2020)... ... January 08, 2020 , ... Quality Health Care Concierge ... holistic care approach and to maintain a comfortable and preferred lifestyle with their Companion ... passion for holistic care and has been a leader in the healthcare field for ...
(Date:1/7/2020)... N.C. (PRWEB) , ... January 07, 2020 , ... ... of Ian Petersen, MBA, as Executive Director of Foothills at Red Oak Recovery ... as a mentor at one of the nation's leading residential treatment centers for ...
(Date:1/7/2020)... ... January 06, 2020 , ... ... impairment, has announced the Best Memory Care Facilities in Lakeland, Florida. The guide ... and amenities. , According to the Alzheimer’s Association , 5.6 million ...
Breaking Medicine News(10 mins):